Amivantamab clinical trials
Also written JNJ-61186372 and RYBREVANT.
Includes 1 study of Amivantamab and Recombinant Human Hyaluronidase.
How each study uses amivantamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the amivantamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 May 2021 · RYBREVANT · BLA 761210 (FDA, Drugs@FDA)
- European Union
- 9 Dec 2021 · Rybrevant · EMEA/H/C/005454 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2024 (9)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 9 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 15
Janssen Research & Development, LLC (14) · Yonsei University (3) · University of Colorado, Denver (1) · M.D. Anderson Cancer Center (1) · AstraZeneca (1) · Institute of Cancer Research, United Kingdom (1) · Trisha Wise-Draper (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Lazertinib (3) · Capmatinib (1) · Tepotinib (1) · Osimertinib (1) · Docetaxel (1) · Mutant-selective EGFR Inhibitor JIN-A02 (1) · FOLFIRI-Ziv-aflibercept Regimen (1) · FOLFIRI Regimen (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Amivantamab is the comparator. A study of two new drugs counts under both.
- 1Izalontamab brengitecan · Bristol-Myers Squibb · next primary completion Dec 2028
Reaching primary completion within a year · 12
Studies that test amivantamab.
- Nov 2026A Study of Amivantamab in People With Esophagogastric CancerPhase 2 · Memorial Sloan Kettering Cancer Center
- Dec 2026Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerPhase 1 · Janssen Research & Development, LLC
- Feb 2027A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerPhase 1 · Janssen Research & Development, LLC
- Apr 2027A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal CancerPhase 1/2 · Janssen Research & Development, LLC
- Apr 2027A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerPhase 1/2 · Janssen Research & Development, LLC
- May 2027An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.Phase 2 · Yonsei University
- May 2027Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)Phase 2 · Gruppo Oncologico del Nord-Ovest
- May 2027Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibPhase 2 · Janssen Research & Development, LLC
- Jul 20275G-EMERALD: Amivantamab in Malignant Brain TumoursPhase 1 · Institute of Cancer Research, United Kingdom
- Jul 2027Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)Phase 2 · University Hospital, Essen
Studies
Open first, then newest update. How each study uses amivantamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 31
- Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune SystemRecruitingPhase 2National Cancer Institute (NCI)NCT07042295Written as Amivantamab and Recombinant Human Hyaluronidase
- A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck CancerRecruitingPhase 1/2Janssen Research & Development, LLCNCT06385080Written as Amivantamab
- A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyRecruitingPhase 3Janssen Research & Development, LLCNCT06750094Written as Amivantamab
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerRecruitingPhase 3Janssen Research & Development, LLCNCT06662786Written as Amivantamab
- A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal CancerRecruitingPhase 1/2Janssen Research & Development, LLCNCT05379595Written as Amivantamab IV
- A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerRecruitingPhase 3Janssen Research & Development, LLCNCT07276399Written as Amivantamab
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT06116682Written as Amivantamab
- Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell CarcinomaNot yet recruitingPhase 2Latin American Cooperative Oncology GroupNCT07808359Written as Amivantamab
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT05845450Written as Amivantamab
- JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI FailureNot yet recruitingPhase 1Yonsei UniversityNCT07798921Written as JIN-A02 in Combination with Amivantamab
- Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)Not yet recruitingPhase 2Yonsei UniversityNCT07507188Written as Amivantamab SC + Chemotherapy (Carboplatin IV & Pemetrexed IV)
- Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.RecruitingPhase 2Fondazione Ricerca TraslazionaleNCT07392658Written as Amivantamab
- Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)RecruitingPhase 2University Hospital, EssenNCT06784791Written as Amivantamab Intravenous
- An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.Not yet recruitingPhase 2Yonsei UniversityNCT06855849Written as Amivantamab + FOLFIRI
- A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)RecruitingPhase 2Vall d'Hebron Institute of OncologyNCT03767075Written as Amivantamab
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04487080Written as Amivantamab
- A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04988295Written as Amivantamab
- Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerActive, not recruitingPhase 1Janssen Research & Development, LLCNCT02609776Written as Amivantamab
- A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerActive, not recruitingPhase 1/2Janssen Research & Development, LLCNCT05488314Written as Amivantamab
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibActive, not recruitingPhase 2Janssen Research & Development, LLCNCT06120140Written as Amivantamab IV
See all 31 studies that test amivantamab →
Given beside what is tested · 14 — amivantamab is usual care or a partner of the new treatment
- A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Janssen Research & Development, LLCNCT06667076Written as Amivantamab
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingPhase 2Janssen Research & Development, LLCNCT05498428Written as Amivantamab
- A Study of JNJ-95437446 in Participants With Advanced-Stage Solid TumorsRecruitingPhase 1Janssen Research & Development, LLCNCT07107230Written as Amivantamab
- A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCRecruitingPhase 2Janssen Research & Development, LLCNCT07586202Written as Amivantamab
- A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung CancerRecruitingPhase 1/2Janssen Research & Development, LLCNCT07227025Written as Amivantamab
- ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCRecruitingPhase 1ORIC PharmaceuticalsNCT06816992Written as ORIC-114 Dose 1 + amivantamab
- Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKIActive, not recruitingPhase 2ETOP IBCSG Partners FoundationNCT05601973Written as Amivantamab
- Premedication to Reduce Amivantamab Associated Infusion Related ReactionsActive, not recruitingPhase 2Janssen Research & Development, LLCNCT05663866Written as Amivantamab
- A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerActive, not recruitingPhase 1/2Janssen Research & Development, LLCNCT05908734Written as Amivantamab
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04538664Written as Amivantamab
- A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid MalignanciesActive, not recruitingPhase 1Kumquat Biosciences Inc.NCT06507306Written as Amivantamab
- Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor MutationsCompletedPhase 2Latin American Cooperative Oncology GroupNCT05299125Written as Amivantamab
- A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT04965090Written as Amivantamab
- FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsTerminatedPhase 1Fate TherapeuticsNCT05395052Written as Amivantamab
As the comparator · 1 — what is tested is compared with amivantamab
Codes
What other systems call amivantamab · ClinicalTrials.gg INT001661
- MeSH (NLM) C000718215amivantamabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0JSR7Z0NB6AMIVANTAMABConfirmed FDA, NLM, Wikidata
- RxNorm 2549199One source FDA
- Wikidata Q106957199amivantamabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C124993AmivantamabOne source FDA
- DrugBank DB16695One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718215 | amivantamab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0JSR7Z0NB6 | AMIVANTAMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2549199 | — | One source FDA |
| Wikidata | Q106957199 | amivantamab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C124993 | Amivantamab | One source FDA |
| DrugBank | DB16695 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.